Creative Medical reports progress in Type 2 Diabetes treatment

PHOENIX - Creative Medical (TASE:PMCN) Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology firm specializing in regenerative medicine with a market capitalization of approximately $7 million, has revealed promising one-year follow-up results from its AlloStem™ (CELZ-201) Type 2 Diabetes pilot study. The company’s stock has shown remarkable momentum, gaining over 72% year-to-date, according to InvestingPro data. The study showed an 80% efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels in late-stage patients, without serious adverse effects.

The pilot study comprised 20 participants, with half receiving the CELZ-201 treatment and the other half undergoing optimized medical therapy. The results not only confirmed the safety and efficacy of CELZ-201 but also mirrored the infusion procedure from the company’s ongoing FDA-cleared Type 1 Diabetes clinical trial.

The absence of safety issues with CELZ-201, an off-the-shelf allogenic cell line, suggests its potential as a novel treatment for late-stage Type 2 Diabetes. Creative Medical Technology plans to further develop AlloStem™ for this application and investigate additional uses for the therapy.

Timothy Warbington, President and CEO of Creative Medical Technology, expressed that the positive data marks a significant step towards transforming diabetes care. The company aims to provide innovative treatments for a variety of patients, expanding beyond the current portfolio which includes therapies for early and brittle Type 1 Diabetes as well as late-stage Type 2 Diabetes.

Type 2 Diabetes is a prevalent condition, affecting 90-95% of the 38 million Americans diagnosed with the disease. As the disease advances, many patients require insulin therapy despite initial management through lifestyle changes and oral medications. Diabetes is a leading cause of death in the U.S., and a significant number of adults are prediabetic without being aware of their condition.

Creative Medical Technology Holdings is focused on developing cell therapies for a range of diseases, including endocrinology, immunotherapy, orthopedic, and neurological conditions. While the company’s progress in diabetes treatment shows promise, InvestingPro data reveals current challenges with an EBITDA of -$5.52 million in the last twelve months. Subscribers to InvestingPro can access 12 additional investment tips and comprehensive financial metrics to better evaluate the company’s potential.

In other recent news, Creative Medical Technology Holdings, Inc. has announced a strategic collaboration with Greenstone Biosciences Inc. to utilize Artificial Intelligence (AI) in advancing its stem cell platform for diabetes treatment. The partnership aims to optimize cell function and broaden the scope of regenerative therapies offered by Creative Medical. In a separate development, the biotechnology firm has amended its Articles of Incorporation to increase the number of authorized shares of common stock from 5 million to 25 million.

Furthermore, the company has successfully completed a safety review for its ADAPT clinical trial, which is evaluating the therapeutic cell product CELZ-201 for treating chronic lower back pain. The independent Data Safety Monitoring Board concluded that the trial may continue without modifications. These recent developments underscore Creative Medical’s commitment to advancing regenerative medicine and providing innovative solutions for chronic conditions.

Lastly, Creative Medical has also announced a plan to create multi-gene edited hypoimmune iPSCs designed to evade immune detection and enhance survival and therapeutic potential. This could lead to cell-based regenerative therapies that do not require immunosuppression, significantly improving patient outcomes. These are recent developments in the company’s ongoing efforts to enhance its therapeutic offerings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.